Company
Aukera Therapeutics GmbH
Incorporated
October 2021
Headquarter
Basel
Support
Our drugs keep the cell's growth engine mTORC1 in check
Aukera Therapeutics is a preclinical-stage biotech spin-off from the University of Basel, emerged from pioneering research on mTOR biology. We specialize in leveraging protein design to drive drug discovery on complex targets. Our lead program focuses on developing a first-in-class, fully selective mTORC1 inhibitor, addressing neurological disorders and cancers. We are committed to translating cutting-edge science into transformative therapies that can significantly impact patient lives.
